Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Salubris Pharma Licenses Sintanovo’s Peripherally Restricted KOR Agonist STC007 for Pruritus and Pain Across Greater China

Fineline Cube Mar 30, 2026
Company Deals

China’s Largest Healthcare M&A Fund Acquires Pediatrix Therapeutics, Bolstering Pediatric Specialty Pharma Portfolio

Fineline Cube Mar 30, 2026
Company Deals

Insilico Medicine and Eli Lilly Forge $2.75B AI Drug Discovery Partnership, Centered on Best-in-Class Oral Therapeutic

Fineline Cube Mar 30, 2026
Company Deals

Novartis to Acquire Excellergy for Up to $2 Billion, Adding Next-Gen Anti-IgE Antibody Exl-111 to Immunology Pipeline

Fineline Cube Mar 30, 2026
Company Deals

Huahai Pharma and Almirall Strike $340M Monoclonal Antibody Licensing Deal Targeting Dermatology and Beyond

Fineline Cube Mar 30, 2026
Policy / Regulatory

China State Council Mandates Long-Term Care Insurance System – 0.3% Contribution Rate Targets Severe Disability Coverage Within Three Years

Fineline Cube Mar 26, 2026
Company Drug

Hansoh Pharma’s Uplizna Gains Third NMPA Approval in China for Generalized Myasthenia Gravis, Expanding CD19 Antibody Franchise

Fineline Cube Mar 30, 2026
Company Drug

Huadong Medicine’s YY001 Becomes World’s First Recombinant Botulinum Toxin Approved in China for Glabellar Lines

Fineline Cube Mar 30, 2026
Company Drug

Angel Pharma Gains NMPA Approval for Soquelitinib in Atopic Dermatitis Trial

Fineline Cube Jun 26, 2025

China-based Angel Pharmaceuticals Ltd announced that it has received approval from the National Medical Products...

Company Drug

Biogen’s Phase I Results Highlight Salanersen’s Potential in Spinal Muscular Atrophy

Fineline Cube Jun 26, 2025

Biogen (NASDAQ: BIIB) announced this week topline results from the Phase I study of salanersen...

Company Deals Drug

Kymera and Sanofi Advance IRAK4 Program With Selection of KT-485 for Clinical Development

Fineline Cube Jun 26, 2025

US-based Kymera Therapeutics Inc. (NASDAQ: KYMR) announced updates to its IRAK4-targeted program collaboration with Sanofi....

Company Drug

LG Chem’s Cross-Linked Sodium Hyaluronate Gel Gains NMPA Approval for Midface Use

Fineline Cube Jun 26, 2025

South Korea’s LG Chem announced that its cross-linked sodium hyaluronate gel with lidocaine has received...

Company Deals

Porton Advanced Partners With EVA Pharma to Boost CAR-T Cell Therapy in MENA

Fineline Cube Jun 26, 2025

China-based Contract Development and Manufacturing Organization (CDMO) Porton Advanced Solutions Ltd. has entered into a...

Company Drug

Eli Lilly’s Amyvid Sees FDA-Approved Label Update for Alzheimer’s Diagnosis

Fineline Cube Jun 26, 2025

US-based Eli Lilly & Co. (NYSE: LLY) announced the US Food and Drug Administration (FDA)...

Company Deals

Gilead Signs Licensing Pact With Kymera Therapeutics for CDK2-Targeted MGD

Fineline Cube Jun 26, 2025

US major Gilead Sciences, Inc. (NASDAQ: GILD) this week entered into an exclusive option and...

Company Drug

SineuGene’s ALS Gene Therapy SNUG01 Granted FDA Orphan Drug Designation

Fineline Cube Jun 26, 2025

Beijing-based SineuGene Therapeutics, a developer of gene therapies for brain disorders, announced this week that...

Company Drug

Acotec Scientific Wins NMPA Approval for Armoni-HP Balloon Catheter

Fineline Cube Jun 26, 2025

China-based Acotec Scientific Holdings Ltd (HKG: 6669) announced that it has received marketing approval from...

Company Deals

Immvira Bioscience Files for Hong Kong IPO to Advance Oncolytic Immunotherapy Pipeline

Fineline Cube Jun 26, 2025

Shenzhen-based Immvira Bioscience Inc. has filed for an initial public offering (IPO) with the Hong...

Company Drug

Genevector’s JWK002 Gains NMPA IND Approval for XLRS Gene Therapy

Fineline Cube Jun 26, 2025

China-based Chengdu Geneector Biotechnology Co., Ltd. (Genevector), a developer of AAV gene therapy drugs, announced...

Company Deals

CMS Plans Secondary Listing on Singapore Exchange to Enhance Shareholder Base and Liquidity

Fineline Cube Jun 25, 2025

China Medical System Holdings Ltd (CMS; HKG: 0867) announced its proposal for a secondary listing...

Company Drug

Livzon’s YJH-012 siRNA Drug Gets NMPA Green Light for Gout Trials

Fineline Cube Jun 25, 2025

China-based Livzon Pharmaceutical Group Inc., (HKG: 1513) announced that its Category 1 chemical drug YJH-012...

Company Medical Device

GE Healthcare Wins FDA Approval for Vizamyl Label Update in Alzheimer’s Detection

Fineline Cube Jun 25, 2025

US medical device and life sciences giant GE Healthcare Technologies Inc., (NASDAQ: GEHC) announced that...

Policy / Regulatory

NHSA Emphasizes Management of Designated Medical Institutions for Healthcare Quality

Fineline Cube Jun 25, 2025

The National Healthcare Security Administration (NHSA) this week released a notification emphasizing the importance of...

Company Deals

Suzhou Porton Biologics Partners with Future Biotechnology to Expand Viral Vector Services

Fineline Cube Jun 25, 2025

China-based Contract Development and Manufacturing Organization (CDMO) Suzhou Porton Biologics Ltd announced this week a...

Company Drug

Lundbeck’s Lu AG13909 Wins Orphan Drug Designations for Congenital Adrenal Hyperplasia

Fineline Cube Jun 25, 2025

Denmark-based pharmaceutical company Lundbeck A/S (OTCMKTS: HLUBF) announced that it has received Orphan Drug Designations...

Company Drug

Henlius Biotech Doses First Patient in Japanese Bridging Trial of Serplulimab for ES-SCLC

Fineline Cube Jun 25, 2025

China-based Shanghai Henlius Biotech Inc. (HKG: 2696) announced the successful completion of first patient dosing...

Company Drug

C.Q. Pharma’s Prasugrel Clinical Filing Accepted by China’s NMPA

Fineline Cube Jun 25, 2025

China-based C.Q. Pharmaceutical Holding Co., Ltd (SHE: 000950) announced that its clinical application for prasugrel...

Company Drug

BeOne Medicines Launches Ziihera for HER2-High Biliary Tract Cancer in China

Fineline Cube Jun 25, 2025

China-based BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced the official commercial availability...

Posts pagination

1 … 114 115 116 … 643

Recent updates

  • Salubris Pharma Licenses Sintanovo’s Peripherally Restricted KOR Agonist STC007 for Pruritus and Pain Across Greater China
  • China’s Largest Healthcare M&A Fund Acquires Pediatrix Therapeutics, Bolstering Pediatric Specialty Pharma Portfolio
  • Hansoh Pharma’s Uplizna Gains Third NMPA Approval in China for Generalized Myasthenia Gravis, Expanding CD19 Antibody Franchise
  • Insilico Medicine and Eli Lilly Forge $2.75B AI Drug Discovery Partnership, Centered on Best-in-Class Oral Therapeutic
  • Huadong Medicine’s YY001 Becomes World’s First Recombinant Botulinum Toxin Approved in China for Glabellar Lines
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Salubris Pharma Licenses Sintanovo’s Peripherally Restricted KOR Agonist STC007 for Pruritus and Pain Across Greater China

Company Deals

China’s Largest Healthcare M&A Fund Acquires Pediatrix Therapeutics, Bolstering Pediatric Specialty Pharma Portfolio

Company Drug

Hansoh Pharma’s Uplizna Gains Third NMPA Approval in China for Generalized Myasthenia Gravis, Expanding CD19 Antibody Franchise

Company Deals

Insilico Medicine and Eli Lilly Forge $2.75B AI Drug Discovery Partnership, Centered on Best-in-Class Oral Therapeutic

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.